XRCC1 Genetic Polymorphism Arg399Gln and Prostate Cancer Risk: A Meta-analysis - 06/08/11
Résumé |
Objectives |
To evaluate the association between x-ray cross-complementing gene 1 (XRCC1) genetic polymorphism Arg399Gln and prostate cancer risk using a meta-analysis.
Methods |
A comprehensive search was conducted to identify all case-control studies of XRCC1 Arg399Gln polymorphism and prostate cancer risk. Statistical analysis was performed using the software program Review Manage, version 4.2, and STATA, version 8.0.
Results |
We identified 7 eligible reports, 1733 prostate cancer cases, and 1756 controls. No significant associations were observed between XRCC1 Arg399Gln polymorphism and the risk of prostate cancer in worldwide populations, without any between-study heterogeneity. In the stratified analysis by ethnicity, our results indicated a significant association and recessive genetic mode of XRCC1 Arg399Gln polymorphism with prostate cancer risk in Asian subjects. Asians with the variant Gln/Gln allele were about 43% more likely to have prostate cancer than were those with the genotype Arg/Gln or Arg/Arg. However, our results also suggested that XRCC1 Arg399Gln polymorphism was not significantly associated with prostate cancer in white men.
Conclusions |
The results of the present meta-analysis have indicated that the XRCC1 codon 399 Gln allele might act as a recessive allele in its association with prostate cancer risk in Asians only.
Le texte complet de cet article est disponible en PDF.Plan
This study was supported by grant 30872979 from the National Natural Science Foundation of China. |
Vol 74 - N° 3
P. 648-653 - septembre 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?